Vol. I · No. 1 · Taipei EditionThursday, 14 May 2026 · 2026-W20Last ingest 3d ago · 4/4 feeds

Agency Intel / TW

“Truth · Timing · Tradecraft” — the WPP Media Taiwan review-readiness desk
Dashboard · Roster · MNC Pharma · Novartis Taiwan
№ 98 · The Novartis Taiwan dossier

Novartis Taiwan

台灣諾華股份有限公司
Parent: Novartis AG (NYSE: NVS; SIX: NOVN)
Readiness
74
Greenfield
Capped at 95. Medium confidence — AOR sourced ≥10y ago — relationship inferred · medium-confidence research.
Workspace · saved locally in your browser
Pipeline status
Your notes · Novartis Taiwan
Saves on blur. Stored in your browser only — not synced.

Novartis Taiwan is a top-5 MNC pharma in Taiwan, established 1996 via merger of Ciba-Geigy and Sandoz operations. Post-Sandoz spin-off (Oct 2023), Novartis Taiwan is PURE-PLAY innovative medicines (Rx only). Heavy concentration in cardiovascular (Entresto is one of the top-selling Rx drugs in Taiwan NHI reimbursement), oncology radioligand therapy (Pluvicto/Lutathera — new growth platform), and immunology (Cosentyx). Taiwan Rx DTC is RESTRICTED under Pharmaceutical Affairs Act 藥事法 Article 66 — Rx promotion limited to HCPs only. Consumer spend is therefore (a) corporate brand campaigns, (b) unbranded disease-awareness (heart failure awareness, psoriasis awareness, MS Day), (c) patient association partnerships (中華民國心臟衰竭學會, Taiwan Psoriasis Association, MS Taiwan Society), (d) HCP digital + medical congress sponsorship. Estimated mid-tier ad spend (NT$200-400M).

Signal timeline · last 90 days
0 of 0 shown
No signals captured in the last 90 days. Account is monitored daily — next ingest will pick up MOPS filings + RSS hits automatically.
The arithmetic of 74
score breakdown
Intel depth (5 wedges · M&A, recent)research_depth+38
AOR 8y with Publicis Health (creative — Saatchi Wellness, Digitas Health, Razorfish Health) + Publicis Media (media — Starcom/Zenith/Publicis Health Media)aor_anniversary_5y+36
Total · capped 9574
30-day signal trajectory
0 signals · spend N/A
Intel wedges
5/8
5 of 8 wedges corroborated. Research confidence: medium.
Open playbook →
Recommended posture
Watch closely.
Power of One — Novartis consolidated global creative + media to Publicis Groupe in 2018 (with creative led by Publicis Health and media led by Publicis Media). One of the LARGEST and most strategic pharma AOR consolidations of the decade. Renewed/confirmed multiple times since.